Navigation Links
Jefferson receives $3 million NIH grant to study molecular and genetic mechanisms in platelets
Date:8/27/2010

(PHILADELPHIA) Scientists at Jefferson Medical College have received a four-year, $3 million National Institutes of Health grant funded by the National Heart, Lung and Blood Institute to study variations of platelet function, specifically, the genetics of platelet gene expression. The study aims to find data that can be translated into novel therapeutic strategies and develop better predictors of cardiovascular disease.

"This study is at the leading-edge of platelet genetic research," said principal investigator Paul F. Bray, M.D., the Thomas Drake Martinez Cardeza Professor of Medicine and director, Division of Hematology in the Department of Medicine at Jefferson Medical College of Thomas Jefferson University. "We still have a limited understanding of the control mechanisms regulating platelet gene expression. Some patients have hyper-functioning platelets which can lead to strokes and heart attacks. On the other end of the spectrum there are some patients with bleeding disorders because their platelets don't clot well enough. Thus, we are talking about very common clinical problems affecting huge numbers of people. We are hoping to shed some light on how the balance gets tipped from health to disease via changes in these fascinating and complex blood cells."

The study will focus primarily on looking at platelet microRNA. MicroRNA's modify gene expression in all tissues, but little is known about how they function in platelets.

"We believe microRNAs serve as a rheostat for protein synthesis in platelets," said Bray. "There are thousands of different settings. People who suffer clotting problems may have different levels of platelet microRNAs than do healthy people. We are going to study platelet microRNAs from healthy individuals and determine how these levels correlate with platelet function. Once we know the situation in healthy subjects, we can assess the critical microRNA levels in patients with unhealthy platelet function. This may serve as a biomarker to predict who might be at risk for bleeding or clotting in different clinical settings and to predict who may benefit from specific drug therapies."

The study will be conducted at two centers: Thomas Jefferson University and Baylor-College of Medicine in Houston. 180 healthy patients over the age of 18 will be selected and prescreened for any potential drug interaction that may skew the results.

"This is a little different from traditional clinical studies in that we are looking for healthy, medication-free patients," said Bray. "Invariably hospitalized patients are receiving multiple medications that may alter platelet function and distort the results. Therefore, we will do extensive pre-enrollment screening. Fortunately, it is fairly easy to find large numbers of eligible volunteers at large medical centers like Jefferson and Baylor College of Medicine."


'/>"/>

Contact: Rick Cushman
richard.cushman@jefferson.edu
215-955-2240
Thomas Jefferson University
Source:Eurekalert

Related biology news :

1. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
2. Jefferson Department of Surgery announces new pancreas tumor registry
3. Jefferson scientists discover a key protein regulator of inflammation and cell death
4. Jefferson researcher awarded Landenberger Foundation grant for ALS research
5. Jefferson receives $1.7 million grant to study stem cells in intervertebral discs of the spine
6. US Department of State names UCR entomologist a Jefferson Science Fellow
7. Jefferson scientists identify a new protein involved in longevity
8. Wistar Institute researcher receives New Innovator award from NIH
9. L-1 Identity Solutions Receives $5.9 Million Drivers License Contract Expansion from the State of Mississippi
10. Kount Receives Patent for Device Fingerprinting
11. American College of Medical Genetics receives $13.5M NIH contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... , March 2, 2017 Summary ... to better understand Merck KGaA and its partnering interests ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and ... the partnering activity of one of the world,s leading ... are prepared upon purchase to ensure inclusion of the ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... GREENWOOD VILLAGE, Colo. , March 23, 2017 /PRNewswire/ ... million in Series A financing and note conversion to ... products. Cool Planet is focused on developing products that ... raised nearly $30 million in the last 18 months. ... Coppel and North Bridge Venture Partners. ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
(Date:3/22/2017)... , March 22, 2017 ... fragmented, states a research report by Transparency Market Research ... Inc., Amgen Inc., and AbbVie Inc., accounted for a ... The prominent players in this market are focusing aggressively ... product portfolio, which is likely to lead to market ...
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... Premier executive ... & Life Science Search Firm by Hunt Scanlon Media. , Hunt Scanlon ... and the most widely referenced global news source in the human capital sector. , ...
Breaking Biology Technology: